Fasnorm 150mg Injection

About

Fasnorm 150mg Injection contains Fulvestrant, a selective estrogen receptor degrader (SERD) used in the treatment of hormone receptor-positive, HER2-negative advanced or metastatic breast cancer. It is typically prescribed for postmenopausal women, or men, whose disease has progressed following endocrine therapy. Unlike aromatase inhibitors, Fulvestrant does not inhibit estrogen synthesis but rather binds to the estrogen receptor (ER) with high affinity, leading to its degradation and downregulation.

This unique mechanism of action effectively blocks estrogen's proliferative effects on cancer cells, making it a valuable therapeutic option for patients who have developed resistance to other endocrine agents. Administered via intramuscular injection, Fulvestrant provides a sustained blockade of estrogen receptor signaling, contributing to improved progression-free survival in eligible patients.

Uses

• Hormone receptor-positive, HER2-negative advanced breast cancer in postmenopausal women.
• Metastatic breast cancer in postmenopausal women with disease progression after endocrine therapy.
• In combination with palbociclib or abemaciclib for HR+, HER2- advanced or metastatic breast cancer.
• Treatment of advanced breast cancer in men with HR+ disease.

Directions For Use

Administered as an intramuscular injection by a healthcare professional, typically once a month after an initial loading dose.

Benefits

• Potent selective estrogen receptor degrader.
• Effective in hormone receptor-positive breast cancer, including those resistant to other endocrine therapies.
• Non-oral administration ensures consistent drug delivery.
• Can be used as monotherapy or in combination with CDK4/6 inhibitors.
• Improves progression-free survival in advanced breast cancer.
• Well-tolerated in many patients with a manageable side effect profile.

Side Effects

• Injection site pain
• Nausea
• Vomiting
• Hot flashes
• Headache
• Fatigue
• Joint pain (arthralgia)
• Back pain
• Bone pain
• Peripheral neuropathy
• Rash
• Anorexia (loss of appetite)

Safety Measures

• Alcohol - No specific contraindication with alcohol, but moderation is advised to avoid exacerbating general side effects like nausea or fatigue.
• Pregnancy - Contraindicated in pregnant women due to potential for fetal harm. Women of childbearing potential should use effective contraception.
• Breastfeeding - Not recommended during breastfeeding due to potential harm to the infant. Discontinue breastfeeding during treatment.
• Liver - Use with caution in patients with moderate to severe hepatic impairment; dose adjustment may be necessary. Monitor liver function regularly.
• Kidney - No dose adjustment is typically required for mild to moderate renal impairment. Use with caution in severe impairment, though data is limited.
• Lung - Generally no specific lung-related precautions, but monitor for any new or worsening respiratory symptoms.

Disclaimer

MedEHub is committed to delivering reliable, expert-reviewd information to help consumers make informed health decisions. However, the content provided on this website is for informational purposes only and is not intended to replace professional medical advice, diagnosis or treatment.

Always consult your doctor for any medical concerns, and discuss your questions about health conditions or medications with a qualified healthcare professional. Do not ignore or delay seeking professional medical advice based on information found on Med E Hub.

Our goal is to complement, not replace, the essential doctor-patient relationship.